180 related articles for article (PubMed ID: 28980909)
1. Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?
Martini G; Campus S; Raffeiner B; Boscarol G; Meneghel A; Zulian F
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):211-213. PubMed ID: 28980909
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil.
Martini G; Ramanan AV; Falcini F; Girschick H; Goldsmith DP; Zulian F
Rheumatology (Oxford); 2009 Nov; 48(11):1410-3. PubMed ID: 19713439
[TBL] [Abstract][Full Text] [Related]
3. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
Soh HJ; Samuel C; Heaton V; Renton WD; Cox A; Munro J
Rheumatol Int; 2019 May; 39(5):933-941. PubMed ID: 30838436
[TBL] [Abstract][Full Text] [Related]
4. A Case of Pansclerotic Morphea Treated With Tocilizumab.
Zhang A; Nocton J; Chiu Y
JAMA Dermatol; 2019 Mar; 155(3):388-389. PubMed ID: 30649148
[No Abstract] [Full Text] [Related]
5. Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts.
Ventéjou S; Schwieger-Briel A; Nicolai R; Christen-Zaech S; Schnider C; Hofer M; Bogiatzi S; Hohl D; De Benedetti F; Morren MA
Front Immunol; 2021; 12():656407. PubMed ID: 33767715
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.
Ortiz-Sanjuán F; Blanco R; Calvo-Rio V; Narvaez J; Rubio Romero E; Olivé A; Castañeda S; Gallego Flores A; Hernández MV; Mata C; Ros Vilamajo I; Sifuentes Giraldo WA; Caracuel MA; Freire M; Gómez Arango C; Llobet J; Manrique Arija S; Marras C; Moll-Tuduri C; Plasencia-Rodriguez C; Roselló R; Urruticoechea A; Velloso-Feijoo ML; Del Blanco J; González-Vela MC; Rueda-Gotor J; Pina T; Loricera J; González-Gay MA
Arthritis Rheumatol; 2014 Jun; 66(6):1659-65. PubMed ID: 24515813
[TBL] [Abstract][Full Text] [Related]
7. Juvenile localised scleroderma: a retrospective review of response to systemic treatment.
Cox D; O' Regan G; Collins S; Byrne A; Irvine A; Watson R
Ir J Med Sci; 2008 Dec; 177(4):343-6. PubMed ID: 18941862
[TBL] [Abstract][Full Text] [Related]
8. IL-6 blockers in systemic onset juvenile idiopathic arthritis.
Barone P; Pignataro R; Garozzo MT; Leonardi S
Immunotherapy; 2016; 8(1):79-87. PubMed ID: 26642378
[TBL] [Abstract][Full Text] [Related]
9. New developments in juvenile systemic and localized scleroderma.
Foeldvari I
Rheum Dis Clin North Am; 2013 Nov; 39(4):905-20. PubMed ID: 24182860
[TBL] [Abstract][Full Text] [Related]
10. Combining PUVA therapy with systemic immunosuppression to treat progressive diffuse morphoea.
Rose RF; Goodfield MJ
Clin Exp Dermatol; 2005 May; 30(3):226-8. PubMed ID: 15807674
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma.
Lythgoe H; Baildam E; Beresford MW; Cleary G; McCann LJ; Pain CE
Rheumatology (Oxford); 2018 Feb; 57(2):398-401. PubMed ID: 29077971
[No Abstract] [Full Text] [Related]
12. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis.
Vaglio A; Catanoso MG; Spaggiari L; Magnani L; Pipitone N; Macchioni P; Pulsatelli L; Nicastro M; Becchi G; Corradi D; Versari A; Boiardi L; Salvarani C
Arthritis Rheum; 2013 Sep; 65(9):2469-75. PubMed ID: 23740665
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children.
Weibel L; Sampaio MC; Visentin MT; Howell KJ; Woo P; Harper JI
Br J Dermatol; 2006 Nov; 155(5):1013-20. PubMed ID: 17034534
[TBL] [Abstract][Full Text] [Related]
14. PUVA therapy for disabling pansclerotic morphoea of children.
Todd DJ; Askari A; Ektaish E
Br J Dermatol; 1998 Jan; 138(1):201-2. PubMed ID: 9536257
[No Abstract] [Full Text] [Related]
15. Successful tocilizumab treatment in a child with refractory Takayasu arteritis.
Bravo Mancheño B; Perin F; Guez Vázquez Del Rey Mdel M; García Sánchez A; Alcázar Romero PP
Pediatrics; 2012 Dec; 130(6):e1720-4. PubMed ID: 23147976
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis.
Muselier A; Bielefeld P; Bidot S; Vinit J; Besancenot JF; Bron A
Ocul Immunol Inflamm; 2011 Oct; 19(5):382-3. PubMed ID: 21970668
[TBL] [Abstract][Full Text] [Related]
18. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
19. Systemic sclerosis and localized scleroderma in childhood.
Zulian F
Rheum Dis Clin North Am; 2008 Feb; 34(1):239-55; ix. PubMed ID: 18329543
[TBL] [Abstract][Full Text] [Related]
20. Scleroderma "en coup de sabre" With Epilepsy and Uveitis Successfully Treated With Tocilizumab.
Osminina M; Geppe N; Afonina E
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):356-358. PubMed ID: 29929808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
